^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19 and CD22 targeted prime CAR-T

    i
    Other names: CD19 and CD22 targeted prime CAR-T
    Associations

    News

    Trials
    Company:
    Chongqing Precision Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jan 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
    |
    CD19 expression • CD22 positive • CD22 expression • IL10 elevation
    |
    CD19 and CD22 targeted prime CAR-T